Questions and responses All Sessions January 17, 1994, to present

With regard to Veterans Affairs Canada contracting Partners in Canadian Veterans Rehabilitation Services to provide rehabilitation services to veterans, since the contract began: (a) how many veterans have been referred by Veterans Affairs Canada to Partners in Canadian Veterans Rehabilitation Services, broken down by fiscal year; (b) how many referrals resulted in veterans receiving rehabilitation or related services through Partners in Canadian Veterans Rehabilitation Services, broken down by fiscal year; (c) what is the total amount paid by Veterans Affairs Canada to Partners in Canadian Veterans Rehabilitation Services since inception, broken down by fiscal year; (d) what are the details of all contracts between Veterans Affairs Canada and Partners in Canadian Veterans Rehabilitation Services, including, for each, the (i) date, (ii) initial value, (iii) current value, if different from the initial value, (iv) duration, (v) description of the services provided; and (e) what is the average and total cost per veteran served through Partners in Canadian Veterans Rehabilitation Services, broken down by fiscal year?

With regard to Health Canada, the Public Health Agency of Canada, the National Advisory Committee on Immunization and the childhood vaccine schedule: (a) what vaccines are currently included on the routine childhood immunization schedule in Canada, including, for each product or combination product, (i) the antigens contained, (ii) the recommended ages of administration, (iii) the total number of doses, (iv) the usual number of injections per vaccine, (v) any differences in the schedule by province or territory; (b) what was the date of first authorization in Canada and the date of first inclusion on the routine childhood schedule, by province or territory, where applicable, for each vaccine currently or previously on the routine childhood schedule; (c) with respect to pre-authorization clinical trials for each vaccine that has ever been on the childhood schedule in Canada, (i) which products were evaluated in randomized, controlled trials using an inert placebo (for example, normal saline), (ii) for each such trial, what was the duration of formal safety follow-up after each dose, (iii) how many children were enrolled in each trial, by age group, (iv) for combination vaccines, how were safety signals attributed to individual antigens; (d) for vaccines that were not evaluated against an inert placebo, (i) what were the control comparators (for example, active comparator vaccine, adjuvant-only, other), (ii) what rationales did Health Canada, the Public Health Agency of Canada or the National Advisory Committee on Immunization rely upon in accepting those comparators for the purposes of safety and efficacy assessment; (e) since the authorization of the first routine childhood vaccine in Canada, have Health Canada, the Public Health Agency of Canada or the National Advisory Committee on Immunization commissioned, funded, or formally reviewed studies that examined (i) adverse events following the concomitant administration of more than one vaccine at the same visit in children, (ii) long-term health outcomes in vaccinated versus unvaccinated, or differently vaccinated, cohorts (now adults) and, if so, what are the titles, authors, years of publication, study designs, populations studied, and key findings of each such study; (f) what studies have Health Canada, the Public Health Agency of Canada or the National Advisory Committee on Immunization commissioned, funded, reviewed, or relied upon to assess potential associations between single or combination childhood vaccinations and (i) autism spectrum disorder, (ii) sudden infant death syndrome, including, for each study, the title, authors, year of publication, study design, population size and age range, vaccination exposure definitions (for example, specific antigens, timing, number of concomitant doses), comparator groups, primary outcomes, and key findings with respect to causation, risk elevation, or absence of association; (g) with respect to the early poliomyelitis vaccines used in Canada, (i) what testing identified contamination with Simian Virus 40, (ii) who conducted this testing, (iii) on which vaccine lots used in Canada was the presence of Simian Virus 40 confirmed, (iv) what evidence was available to Health Canada, the Public Health Agency of Canada or their predecessor bodies concerning the oncogenic potential of Simian Virus 40 at the time; (h) what long-term epidemiologic or cohort studies, whether Canadian or international, have Health Canada, the Public Health Agency of Canada or the National Advisory Committee on Immunization reviewed or relied upon that specifically assessed cancer incidence or other chronic disease outcomes among individuals who received polio vaccines known or suspected to be contaminated with Simian Virus 40, including, for each study, the (i) title, (ii) authors, (iii) year, (iv) jurisdiction, (v) population size, (vi) duration of follow-up, (vii) main conclusions; (i) what is Health Canada’s current policy and regulatory guidance regarding the safe use, prohibition, or control of Simian Virus 40 or Simian Virus 40-derived materials in human vaccine manufacture, including (i) any applicable regulations, guidance documents or standards, (ii) requirements for testing of cell substrates and vaccine lots for Simian Virus 40 or other oncogenic viruses, (iii) how compliance is verified and enforced; (j) what post-market (Phase IV) safety surveillance systems and enhanced surveillance activities are in place for routine childhood vaccines in Canada, and, for each system, (i) what types of adverse events following immunization are monitored, (ii) how are signals related to multi-dose or multi-vaccine visits detected and evaluated, (iii) how do Health Canada, the Public Health Agency of Canada or the National Advisory Committee on Immunization use this data to update the childhood vaccine schedule or product monographs; (k) what guidance, if any, has the National Advisory Committee on Immunization issued regarding (i) the maximum number of vaccine injections recommended at a single visit for infants and children, (ii) the circumstances in which deferral, spacing or alternative scheduling is recommended for safety reasons, (iii) the evidence base cited in developing such guidance; (l) have Health Canada, the Public Health Agency of Canada or the National Advisory Committee on Immunization made any changes to Canada’s routine childhood vaccine schedule since January 1, 2020, in response to or alignment with modifications made in the United States; (m) has Health Canada, the Public Health Agency of Canada or the National Advisory Committee on Immunization conducted or commissioned formal comparisons of Canada’s schedule with those in other jurisdictions such as Japan, Germany, and Denmark, including any resulting recommendations or adjustments; and (n) if the answer to (m) is affirmative, what are the (i) dates, (ii) rationales, (iii) specific changes considered or implemented, (iv) references to relevant National Advisory Committee on Immunization statements, reports, or guidance documents?

With regard to the Public Health Agency of Canada and Health Canada COVID-19 pandemic response: (a) did the Public Health Agency of Canada or Health Canada conduct, assign or fund random representative national seroprevalence surveys for SARS-CoV-2 during the pandemic; (b) if the answer to (a) is affirmative, for each survey, (i) what was the name of the agency or institutions that did the testing, (ii) what were the dates of the testing, (iii) what were the results stratified by age and region; (c) if the answer to (a) is affirmative, what were the age stratified infection fatality rates based on this data; (d) if the answer to (a) is affirmative, (i) what was the primary test used for serological detection, (ii) how was it independently validated for sensitivity and specificity, (iii) was it primarily used with dry blood samples; (e) if the answer to (a) is affirmative, (i) was any other SARS-CoV-2 protein tested for antibodies besides the nucleocapsid or spike protein, (ii) were the following antibodies assayed: IgG1, IgG3, IgA, and IgM; (f) if the Public Health Agency of Canada or Health Canada did not conduct, assign or fund random, representative national seroprevalence surveys for SARS-CoV-2 during the pandemic, why not; and (g) why did the Government of Canada appoint an external Immunity Task Force to conduct serosurveys rather than leveraging internal research personnel, existing research partnerships and rapid research protocols, as published in the Canadian Influenza Pandemic Plan 2018, which is not confined to influenza pandemics?

With regard to the Public Health Agency of Canada, Health Canada, the National Advisory Committee on Immunization and COVID-19 vaccine deaths and injuries: (a) on what date did each government department first receive a report of a death from the (i) AstraZeneca, (ii) Pfizer, (iii) Moderna, COVID-19 vaccine; (b) what are the dates of the meetings in which the deaths from COVID-19 vaccines were discussed; (c) for each meeting in (b), what are the (i) names of those who attended the meeting, (ii) titles of those who attended the meeting, (iii) conclusions reached during the meeting; (iv) names of process documents modified after the meeting; (d) did the Public Health Agency of Canada or Health Canada develop a subcommittee to address deaths from the COVID-19 vaccines, and, if so, (i) who was on this committee, (ii) how often did it meet, (iii) what are the dates of the meetings, (iv) what were the outcomes of these meetings, (v) what are the names of the documents associated with these meetings; (e) did a government department notify any Member of Parliament or their staff about deaths from COVID-19 vaccines, and, if so, for each notification, (i) who was notified, (ii) how were they notified, (iii) on what date were they notified; (f) on what date did a government department first receive a report of a spontaneous abortion from a COVID-19 vaccine; (g) what are the dates of the meetings discussing the spontaneous abortions in (f); (h) for each meeting in (g), what are the (i) names of those who attended the meeting, (ii) titles of those who attended the meeting, (iii) conclusions reached during the meeting, (iv) names of process documents modified after the meeting; (i) did a government department notify any Member of Parliament or their staff about spontaneous abortions from COVID-19 vaccines, and, if so, for each notification, (i) who was notified, (ii) how were they notified, (iii) on what date were they notified; (j) on what date did a government department first receive a report of (i) a heart attack, (ii) a stroke, (iii) myocarditis, (iv) pericarditis from COVID-19 vaccines; (k) what are the dates of the meetings discussing the reports in (j); (l) for each meeting in (k) what are the (i) names of those who attended the meeting, (ii) titles of those who attended the meeting, (iii) conclusions reached during the meeting; (iv) names of process documents modified after the meeting; and (m) did a government department notify any Member of Parliament or their staff about heart attacks, strokes, myocarditis or pericarditis from COVID-19 vaccines, and if so, for each notification, (i) who was notified, (ii) how were they notified, (iii) on what date were they notified, (iv) what was the subject of the notification?

With regard to the response to Order Paper Question Q-763 and Health Canada, the Public Health Agency of Canada and the National Advisory Committee on Immunization, Canadian Institutes of Health Research, the National Research Council, and the costs and expenses associated with COVID-19 vaccine benefits and risks since January 2020: (a) how much money was spent investigating and researching the benefits of the COVID-19 vaccine, broken down by (i) month, (ii) expense or project name, (iii) start and end date, (iv) total cost, (v) description; (b) how much money was spent investigating and researching the risks and adverse effects of the COVID-19 vaccine, broken down by (i) month, (ii) expense or project name, (iii) start and end date, (iv) total cost, (v) description; (c) how much money was spent informing Canadians of the benefits of the COVID-19 vaccine, broken down by (i) expense name, (ii) date, (iii) cost, (iv) overview of expense; (d) how much money was spent informing Canadians about the risks and adverse effects of the COVID-19 vaccine, broken down by (i) expense name, (ii) date, (iii) cost, and (iv) overview of expense; (e) how much money was spent promoting the COVID-19 vaccines, including grants, working groups, research projects, contractors, advertising, influencers, surveys, publications and behavioural assessments, broken down by (i) type of promotion, (ii) expense, (iii) date, (iv) total cost, (v) description; (f) how much money was spent informing health professionals of the risks and adverse effects of the COVID-19 vaccine, broken down by (i) expense, (ii) date, (iii) total cost, (iv) description; (g) how much money was spent informing Government of Canada employees, contractors, or federally regulated companies on the benefits of the COVID-19 vaccine, broken down by (i) expense, (ii) date, (iii) description; and (h) how much money was spent informing Government of Canada employees, contractors or federally regulated companies on the risks and adverse effects of the COVID-19 vaccine, broken down by (i) expense, (ii) date, (iii) description?

With regard to government information on Canadian and international experiences with medical assistance in dying: (a) what comparative studies has the government conducted on psychiatric medical assistance in dying in Belgium, the Netherlands or other jurisdictions; (b) which safeguards adopted abroad to mitigate risks of premature or inappropriate psychiatric medical assistance in dying have not been implemented in Canada, and why; and (c) how does Canada’s medical assistance in dying regime compare internationally in terms of permissiveness, oversight and eligibility thresholds?

With regard to federal oversight of medical assistance in dying: (a) how many cases of medical assistance in dying where safeguards were found not to have been followed have been reported to Health Canada since 2016, broken down by year and province; (b) what corrective or enforcement actions were taken in each case; (c) what audits or spot reviews, if any, has Health Canada conducted of medical assistance in dying case files to verify compliance with Criminal Code safeguards; and (d) what measurable outcomes or indicators does the government use to assess whether medical assistance in dying safeguards against coercion are effective, particularly for persons with disabilities, those in poverty and Indigenous Canadians?

With regard to Health Canada’s review of the COVID-19 modRNA vaccine products: (a) did Health Canada consider the specific nature of the nanotechnology of the lipid particles used for the modRNA vaccine delivery; (b) if the answer to (a) is affirmative, what was their assessment; (c) why was the fact that modRNA vaccines contain nanotechnology omitted from the product monograph-label; (d) did Health Canada assess the toxicity of pegylated nanoparticles, specifically the risk for complement activation-related pseudoallergy (CARPA) with the lipid nanoparticles used in the mRNA vaccines; (e) if the answer to (d) is affirmative, why was this not included in the product labelling; (f) if the answer to (d) is negative, why wasn’t this assessed; (g) did Health Canada assess the risk of toxicity due to the nanoformat of these vaccines; (h) if the answer to (g) is affirmative, what was the assessment result; (i) if the answer to (g) is negative, why not; (j) did Health Canada assess the lipid nanoparticles as a novel excipient; (k) if the answer to (j) is affirmative, what was the assessment; (l) if the answer to (j) is negative, why not; (m) with respect to nanotechnology products and their unique properties and behaviours, particularly in their application to the modRNA vaccines, did Health Canada examine (i) the safety, (ii) the effectiveness, (iii) the risk to the environment, (iv) its specific regulatory status; (n) if the answers to (m)(i) through (m)(iv) are affirmative, what were the assessment results; (o) if the answers to (m)(i) through (m)(iv) are negative, why not; (p) how do established safe levels of DNA apply (i) when using pegylated lipid nanoparticles as a delivery system, (ii) when a product that contains pegylated lipid nanoparticles requires repeated dosing; and (q) what assessment was performed to assess the risk of residual DNA when using pegylated lipid nanoparticles as a delivery system in a vaccine which requires repeated dosing?

With regard to Health Canada, the Public Health Agency of Canada and the National Advisory Committee on Immunization and their statement, “the benefits of the COVID-19 vaccines outweigh the risks”: (a) what are the benefits of the COVID-19 vaccines, broken down by (i) benefit, (ii) supporting studies or documents and their published date, (iii) start and end dates of the benefit analysis, (iv) name and title of those who analyzed the benefit; (b) what are the risks of the COVID-19 vaccines, broken down by (i) risk, (ii) supporting studies or documents and their published dates, (iii) date on which the risk was identified, (iv) start and end dates of the risk analysis, (v) name and title of those who analyzed the risk; (c) was a risk and benefit analysis performed for each COVID-19 vaccine product; (d) if the answer to (c) is affirmative, (i) what are the start and end dates of each analysis, (ii) what are the differences between the product analysis results; (e) was a separate risk and benefit analysis performed for (i) various age groups, (ii) genders, (iii) pregnant women, (iv) the immunocompromised, (v) First Nations and Indigenous populations; (f) if the answer to (e) is affirmative, for each group in (e), what are the (i) start and end dates for each analysis performed, (ii) name and title of those who performed them; (g) was a risk and benefit analysis performed for Canadians who were previously infected with COVID-19; and (h) if the answer to (g) is affirmative, for each analysis performed, what (i) was the start date, (ii) was the end date, (iii) were the conclusions of the analysis?

With regard to the 2021 recommendation of the Veterans Ombud to the government concerning mental health treatment benefits for family members of veterans in their own right for the conditions related to military service, in which the Ombud recommended government funded mental health treatment independent of the veteran’s treatment plan and regardless of whether the veteran is engaging in treatment: (a) does it remain the position of the government that it accepts this recommendation, and, if not, when the did the position change; (b) what is the government’s current progress in implementing this recommendation; (c) what tangible steps have been taken to implement this recommendation, and on what date was each step taken; (d) how many times, and through which methods, has the government communicated with the Veterans Ombud or her office concerning the implementation of this recommendation, and on what dates did the communications occur; and (e) how many times has the Department of Veterans Affairs communicated with or received communication from other government departments or agencies related to the recommendation, and what are the details of each communication, including (i) the date, (ii) who was involved, (iii) the type of communication, (iv) a summary of what was communicated?

With regard to medical assistance in dying and Veterans Affairs Canada, since September 2022: (a) how many times has a (i) Veterans Affairs Canada employee, (ii) third-party contracted by Veterans Affairs Canada, advised, suggested, or discussed medical assistance in dying with a veteran; (b) what is Veterans Affairs Canada's current policy regarding its (i) employees, (ii) contractors, suggesting medical assistance in dying to veterans; and (c) on what date did the policy in (b) come into effect?

With regard to Health Canada and Public Health Agency of Canada messaging about the safety of COVID-19 vaccines during pregnancy and lactation and website messaging that reads, “Vaccination is an important part of a healthy pregnancy, with health benefits for both the pregnant person and their baby. Several vaccines are routinely recommended during pregnancy, including COVID-19 vaccines [...] Evidence suggests that COVID-19 vaccination during pregnancy helps to prevent: COVID-19 infection and the risk of hospitalization from COVID-19 in infants under 6 months of age” and the government response to Order Paper Question Q-2163 from the 44th Parliament, which reads, “As indicated in the specific Product Monographs, it is noted that the safety and efficacy of these vaccines in pregnant women have not yet been established. No indication for use in pregnant or lactating women was sought by the vaccine sponsors or authorized by Health Canada [...] Health Canada has not approved any safety claims with regard to pregnant and lactating women”: (a) how does Health Canada and the Public Health Agency of Canada explain these two conflicting statements; (b) who wrote the statement on the government's website and who approved it; and (c) who wrote the statement in the response to Q-2163 and who approved it?

With regard to the recommendations in Health Canada’s publication through the National Advisory Committee on Immunization titled, “Vaccination and pregnancy: COVID-19”: (a) how do these recommendations differ from the May 27, 2025, announcement by the United States of America’s Health and Human Services, stating the COVID-19 vaccine would no longer be included in the Centers for Disease Control and Prevention’s recommended immunization schedule for healthy pregnant women and healthy children (herein referred to as “cohort”) citing “mixed data” on booster safety and efficacy for pregnant women while seeking stricter clinical trials for vaccine approvals in healthy individuals under 65; (b) did communications occur, related to the Health and Human Services announcement, between Health Canada, the National Advisory Committee on Immunization or the Public Health Agency of Canada and (i) Health and Human Services, (ii) the United States of America’s Food and Drug Administration, (iii) the United States’Centers for Disease Control and Prevention, (iv) the United Kingdom’s Medicines & Healthcare products Regulatory Agency, (v) the European Medical Agency; (c) if the answer to (b) is affirmative, what (i) were the dates of the communications, (ii) were the modes of communications, (iii) were the names and titles of people included in the communications, (iv) was the outcome; (d) to Health Canada's knowledge, did the Medicines & Healthcare products Regulatory Agency or the European Medical Agency agree with Health Canada’s recommendations for the administration of the COVID-19 vaccine to this cohort; (e) does Health Canada, the National Advisory Committee on Immunization or the Public Health Agency of Canada have mixed data regarding booster safety and efficacy of the COVID-19 vaccine in this cohort, and, if so, how does this impact the risk-benefit analysis; (f) is Health Canada , the Public Health Agency of Canada or the National Advisory Committee on Immunization including the same or different data than the United States of America’s Health and Human Services, Food and Drug Administration, and Centers for Disease Control and Prevention in the decision to continue recommending the COVID-19 vaccines for this cohort; (g) what clinical trials or data is Health Canada, the National Advisory Committee on Immunization and the Public Health Agency of Canada including in their decision that gives them confidence to continue recommending these vaccines that differs from the United States of America’s Health and Human Services, the Food and Drug Administration, and the Centers for Disease Control and Prevention; (h) is Health Canada planning to request stricter clinical trials for vaccine approvals in healthy individuals under 65 in the future, and, if not, why not; (i) if the answer to (h) is affirmative, what additional vaccine clinical trial requirements will be needed for approval; (j) are there plans to change the recommendations with respect to the COVID-19 vaccine in this cohort; and (k) if the answer to (j) is affirmative, when will these recommendations be announced, and what will they include?

With regard to the findings of the United Nations Committee on the Rights of Persons with Disabilities with respect to Canada's implementation of the Convention on the Rights of Persons with Disabilities: (a) what is the position of the government regarding these findings; (b) is the government considering changing any previous policies or positions in response to this report; (c) is the government considering repealing or making changes, in particular to Track 2 Medical Assistance in Dying, in response to this report, and, if so, what is the government considering repealing or changing; and (d) what are the government's legal obligations in light of the findings of the committee, in light of the fact that Canada is a signatory to the Convention on the Rights of Persons with Disabilities?

With regard to communications sponsored by the government during the COVID-19 pandemic: (a) which individual or agency developed the “Pregnancy, childbirth and caring for a newborn during the COVID-19 pandemic” communication, which was first published on July 13, 2021, and last updated on October 25, 2023; (b) who provided the final approval of the communication in (a) and when; (c) which individual or agency developed the narrative for the video titled, “Are there any ingredients in the COVID-19 vaccines that I should be concerned about”, narrated by Dr. Ayesha Raza; (d) who provided the final approval of the communication in (c) and when; (e) which individual or agency developed the narrative for the video titled, “Can the COVID-19 vaccines affect fertility”, narrated by Dr. Darine El-Chaâr; (f) who provided the final approval of the communication in (e) and when; (g) on December 23, 2021, which individual or agency developed the advice to Canadians about the interchangeability of vaccines found on the government's website, titled, “COVID-19 vaccine: Canadian Immunization Guide, For health professionals, Notice”; and (h) who provided the final approval of the communication in (g) and when?

With regard to Veterans Affairs Canada’s public and private directives to veterans concerning the certification of service dogs: (a) what are the directives currently issued; (b) how has each directive changed between January 1, 2016, and today; and (c) from January 1, 2016, to today, what are the details of any internal or external communications or briefing materials between Veterans Affairs Canada officials or with other departments, stakeholders, or individuals relating to the public and private directives issued to veterans regarding the certification of service dogs, including the (i) date, (ii) title, (iii) sender, (iv) recipient, (v) type of communication, (vi) file or tracking number?

With regard to communications sponsored by the government during the COVID-19 pandemic: (a) which individual or agency developed the “Pregnancy, childbirth and caring for a newborn during the COVID-19 pandemic” communication which was first published on July 13, 2021, and last updated on October 25, 2023; (b) who provided the final approval of the communication in (a) and when; (c) which individual or agency developed the narrative for the video titled “Are there any ingredients in the COVID-19 vaccines that I should be concerned about”, narrated by Dr. Ayesha Raza, family physician and women’s health specialist, about the ingredients of the COVID-19 vaccine and how long these vaccines stay in the body, i.e., “they leave the body shortly after vaccination”; (d) who provided the final approval of the communication in (c) and when; (e) which individual or agency developed the narrative for the video titled “Can the COVID-19 vaccines affect fertility”, narrated by Dr. Darine El-Chaâr, maternal fetal medicine specialist at the Ottawa Hospital, and sponsored by the government; (f) who provided the final approval of the communication in (e) and when; (g) on December 23, 2021, which individual or agency developed the advice to Canadians about the interchangeability of vaccines found on the government's website, titled “COVID-19 vaccine: Canadian Immunization Guide, For health professionals, Notice”; and (h) who provided the final approval of the communication in (g) and when?

With regard to the Pain and Suffering Compensation (PSC) administered by Veterans Affairs Canada (VAC), broken down by year since January 1, 2016, and by branch of the Canadian Armed Forces (CAF), for each part of the question: (a) how many CAF members who became eligible for PSC requested (i) monthly payment for life, (ii) to accept a lump sum cash out; (b) of the CAF members who requested a lump sum, how many were (i) retiring, (ii) medically discharged; and (c) what was the total paid out by VAC in PSC lump sum cash outs?

Regarding Health Canada’s (HC) review of the COVID-19 modRNA vaccine products: (a) did HC consider the specific nature of the nanotechnology of the lipid particles used for the modRNA vaccine delivery; (b) if affirmative to (a), what was their assessment; (c) why was the fact that modRNA vaccines contain nanotechnology omitted from the product monograph-label; (d) did HC assess the toxicity of pegylated nanoparticles, specifically the risk for complement activated related pseudoallergy (CARPA) with the lipid nanoparticles used in the mRNA vaccines; (e) if affirmative to (d), why was this not included in the product labelling; (f) if negative to (d) why wasn’t this assessed; (g) did HC assess the risk of toxicity due to the nanoformat of these vaccines; (h) if affirmative to (g), what was the assessment result; (i) if negative to (g), why not; (j) did HC assess the lipid nanoparticles as a novel excipient; (k) if affirmative to (j), what was the assessment; (l) if negative to (j), why not; (m) with respect to nanotechnology products and their unique properties and behaviors particularly in their application to the modRNA vaccines, did HC examine the (i) safety, (ii) effectiveness, (iii) risk to the environment and (iv) its specific regulatory status; (n) if affirmative to (m), (i) through to (iv), what were the assessment results; (o) if negative to (m), (i) through to (iv), why not; (p) how do established safe levels of DNA apply, (i) when using pegylated LNPs as a delivery system, (ii) when a product that contains pegylated LNPs requires repeated dosing; and (q) what assessment was performed to assess the risk of residual DNA when using pegylated LNPs as a delivery system in a vaccine which requires repeated dosing?

With regard to government assistance available to clients of the Resettlement Assistance Program (RAP) of Immigration, Refugees and Citizenship Canada: (a) what is the duration of the program from a client’s date of arrival in Canada to its end; (b) what are the criteria for determining the duration of the program for each client; (c) what are the criteria required for extending the duration of the program, and for how long can it be extended; (d) what are the criteria for determining the allowance amount for each client; (e) what is the total possible amount of the monthly allowance per client category; (f) what is the total possible amount of monthly allowance under the employment incentive policy of the RAP program per client category; (g) what is the total amount to which RAP recipients are entitled per month through the child tax benefit per client category; (h) what is the total amount to which recipients are entitled per month through the RAP housing top-up allowance per client category; (i) what is the total amount of the start-up allowance entitled to clients of the program, broken down by client category; and (j) what are the minimum and maximum allowances of other sources of income available to RAP clients, broken down by client category and type of income?